President Trump wants pharmaceutical production to return to the United States. A shuttered factory in Louisiana shows how ...

Having seen Congress spend money to onshore semiconductor production, pharma groups are pushing for similar incentives for ...

Specialty drugs, especially biologics, will constitute a significant portion of global drug spending by 2029, driven by cancer care costs. Autoimmune diseases and multiple sclerosis are key short-term ...

This analysis reviews the history and current status of biosimilar regulation in the US, concluding that changing the FDA’s interchangeability standards—as proposed by some policy makers—is a ...

The agency will no longer require studies comparing copycat biologics to their branded counterparts, which could help ...